Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients With IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or MDS/MPN
Sponsor: Novartis Pharmaceuticals
Terminated
Slow recruitment. It is not considered likely that the CANFIRE trial will be able to reach the target number of patients. Clinical responders will be further treated within the trial (expected duration: 3 years after stop of enrollment).
A PHASE2 clinical study on Anemia and Myelodysplastic Syndromes, this trial is terminated or withdrawn. The trial is conducted by Novartis Pharmaceuticals and has accumulated 10 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Sep 2023 — Jun 2024 [monthly]
Recruiting PHASE2
-
Dec 2022 — Sep 2023 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
- University of Leipzig
For direct contact, visit the study record on ClinicalTrials.gov .